
At embecta (formerly part of BD), we are singularly focused on improving the lives of people living with diabetes. With a 100-year legacy of developing and providing solutions to the diabetes community, today, we are a global medical technology company and leader in insulin delivery devices. More than 30 million people in over 100 countries rely on our pen needle and syringe products every day. BD is the manufacturer of the advertised products. Privacy Policy: https://www.embecta.com/en-us/about/policies/privacy-policy-statement
Unlock the market timeline & signal feed
7 signals in the last 90 days.
The order this company entered each market — oldest to newest
15 active postings
PQS Operator
Sign up to see the full signal feed
How Embecta's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
EmbectaYou | 2 | 0 | -50% | 6 | 20 |
Senior Regulatory Affairs Specialist
View postingMexico City Metropolitan Area · 4d ago
Marketing Manager, Korea
View postingSeoul, Seoul, South Korea · 5d ago
Business Analyst - Commercial Operations
View postingMontbonnot-Saint-Martin, Auvergne-Rhône-Alpes, France · 6d ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Nidhi Gani, a regulatory affairs expert in cybersecurity and medical devices, discusses her experience and work at Embecta and Northeastern University.
Great Place To Work™ held the 2025 Greater China Best Workplaces™ awards in Shanghai, recognizing organizations excelling in workplace culture.
Great Place To Work hosted the Best Workplaces in Greater China 2025 awards, recognizing 66 companies for excellence in workplace culture across small, medium, and large categories.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Embecta's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.